Needham Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $88 to $85.
November 07, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a Buy rating on CRISPR Therapeutics but lowers the price target from $88 to $85.
The news is directly related to CRISPR Therapeutics. While the maintained Buy rating is positive, the lowered price target might indicate a potential decrease in the stock's value. However, the impact on the stock price is uncertain as it depends on how investors interpret this information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100